Sign In
Buy PLX
$1.96
-0.0300 (-1.51%)
At Close: Jun 03, 2026
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript
10:22am, Monday, 17'th Mar 2025
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
06:50am, Monday, 17'th Mar 2025
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company fo
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum
11:36am, Monday, 24'th Feb 2025
For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- a
Protalix Biotherapeutics gains momentum in the rare disease space: analysts
03:01pm, Tuesday, 04'th Feb 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see sustainable profitability on the horizon. Strong revenue
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
06:50am, Tuesday, 04'th Feb 2025
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel , Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical
Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease in European Union PARMA, Italy and CARMIEL Isra
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript
11:23am, Thursday, 14'th Nov 2024
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - Pr
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
07:18am, Friday, 25'th Oct 2024
CARMIEL, Israel , Oct. 25, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recomb
Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024
08:35am, Monday, 16'th Sep 2024
The Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com The Company invites individual and institutional inves
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes
06:50am, Tuesday, 03'rd Sep 2024
Company is debt-free with no outstanding notes Balance sheet provides sufficient runway for ongoing operations CARMIEL, Israel , Sept. 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Amer
Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript
10:32am, Wednesday, 14'th Aug 2024
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors Dror Bashan - President and
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
06:50am, Wednesday, 14'th Aug 2024
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company f
Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel , June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders. Since
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
08:38am, Wednesday, 29'th May 2024
Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel , May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical com
